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Summary 
The mechanism by which the mammalian mother accepts the implanting fetus as an allograft 
remains unexplained, but is likely to be the result of a combination of factors. Mononuclear cy- 
totrophoblasts, he specialized fetal cells of the placenta that invade the uterus, play an impor- 
tant role. These cells express HLA-G, an unusual major histocompatibility complex class I-B 
molecule, and secrete cytokines and pregnancy-specific proteins that can regulate immune 
function. We investigated whether cytotrophoblasts ecrete interleukin 10 (IL-10), a cytokine 
that potently inhibits alloresponses in mixed lymphocyte reactions. Cytotrophoblasts from all 
stages of pregnancy produced IL-10 in vitro, but neither placental fibroblasts nor choriocarci- 
noma (malignant trophoblast) cell lines did so. Spontaneous IL-10 production averaged 650, 
853, and 992 pg/106 cells in the first, second, and third trimesters of pregnancy, respectively. 
IL-10 secretion dropped ,',~10-fold after the first 24 h of culture, and was paralleled by a de- 
crease in messenger tkNA. IL-10 messenger RNA was detected in biopsies of the placenta nd 
the portion of the uterus that contains invasive cytotrophoblasts, suggesting that this cytokine is 
also produced in vivo. IL-10 secreted by cytotrophoblasts in vitro is bioactive, as determined 
by its ability to suppress interferon ~/production i an allogeneic mixed lymphocyte reaction. 
We conclude that human cytotrophoblast IL-10 may be an important factor that contributes to 
maternal tolerance of the allogeneic fetus. 
D uring human pregnancy, genetically foreign cells from the fetal portion of the placenta invade the uterus. 
This process is the result of differentiation ofthe specialized 
epithelial cells of the placenta, termed trophoblasts (re- 
viewed in 1 and 2). Mononuclear cytotrophoblast tem 
cells are anchored to basement membranes surrounding the 
stromal cores of two types of chorionic villi. In floating 
villi, cytotrophoblasts fuse to form the overlying syncy- 
tium, which is in direct contact with maternal blood, me- 
diating nutrient and gas exchange for the developing fetus. 
In anchoring villi, cytotrophoblasts differentiate by leaving 
their basement membrane and forming columns of cells. 
These cell columns give rise to the invasive subpopulation 
of cytotrophoblasts that attaches to and invades the uterus 
and its arterial system. In response to cytotrophoblast inva- 
sion, the uterine stroma decidualizes and is infiltrated by a 
specific subset of maternal immune cells. As a result, the 
pregnant human uterus contains amixture of fetal and ma- 
ternal cells, the latter being up to 75% immune-competent 
bone marrow-derived cells (3). 
Because of their unique position at the maternal-fetal in- 
terface, placental trophoblast cells are presumed to shield 
the allogeneic fetus from rejection (4, 5), although the mo- 
lecular mechanisms have not been fully defined. Faulk et al. 
(6, 7) suggested that the placenta passively evades immune 
recognition through the absence of classical class I and II 
MHC antigens on syncytiotrophoblast cells. However, 
subsequent s udies revealed that invasive cytotrophoblasts 
express a nonclassical c ass I antigen, HLA-G (8-10). It has 
been suggested that this molecule could function as a uni- 
versal "self"-transplantation antigen, preventing maternal 
imnmne attack of the feto-placental unit (9, 11). 
The localized secretion ofimmunomodulatory factors by 
the placenta may also contribute to survival of the fetal al- 
lograft. Hormones in high concentration at the placental- 
uterine interface, such as progesterone, human placental 
lactogen, prolactin, and estrogens, inhibit lymphocyte reac- 
tivity in vitro (12). Other placental factors with inhibitory 
effects on immune function include pregnancy-associated 
oL2-glycoprotein, pregnancy-associated plasma protein A, 
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and oL-fetoprotein (13). In addition to peptide and steroid 
hormones, the human placenta secretes a variety of  cyto- 
kines, including CSF-1 (14), M-CSF (15), IL-113 (16), IL-6 
(17, 18), and TGF-[3 (19, 20). 
Alloreactive T lymphocyte responses are also suppressed 
by other, as yet undefined substances in cytotrophoblast- 
conditioned medium (21) and in the supernatants from 
cocultures of  cyto- and syncytiotrophoblasts (22). This im- 
munosuppressive activity is very similar to the biological 
effects described for IL-10, an immunoregulatory c tokine 
that inhibits the generation of  alloreactive T cells in mixed 
lymphocyte reactions (MLP,1; 23). To test the possibility 
that IL-10 may be involved in trophoblast-mediated mater- 
nal immune inhibition, we investigated the production of  
IL-10 by several types of  human placental cells, including 
primary cyto- and syncytiotrophoblasts, placental fibro- 
blasts, and choriocarcinoma cell lines. The results of  this 
study show that IL-10 is produced specifically by primary 
cytotrophoblasts in vitro and that this cytokine can inhibit 
an allogeneic immune response. We hypothesize that IL-10 
may play an important role in suppressing potentially 
harmful maternal immune responses in vivo. 
Materials and Methods  
Placental Cell and Tissue Isolation and Culture. Cytotrophoblasts 
were isolated from pooled first- or second- (24, 25) trimester and 
individual third-trimester (26) human placentas by published 
methods. Chorionic viLli were collected immediately after vac- 
uum aspiration and washed three times in wash medium (DME 
H-21, 2.5% FCS, 1% peniciLlin/streptomycin). Placental fibro- 
blasts were isolated from first-trimester placentas as previously de- 
scribed (24). The JAR (27), BeWo (28), and JEG (29) human 
choriocarcinoma ceLl lines (American Type Culture Collection, 
Rockville, MD) were maintained as previously described (24). 
Cytotrophoblasts, choriocarcinoma cell lines, and fibroblasts 
(106) and chorionic villi (0.l g) were cultured in 1 ml of serum- 
free medium (DME H21 MEM containing 2% Nutridoma [Boeh- 
ringer Mannheim, Indianapolis, IN] and 50 I~g/ml gentimicin; 
serum-free medium) in 16-mm culture wells precoated with a 
basement membrane substrate (Matrigel; Collaborative Research 
Inc., Bedford, MA) diluted two parts to one part SFM as de- 
scribed (25). For immunohistochemical studies, cells were plated 
at a density of 2.5 • 10 s cells/ 500 ILl SFM in each well of an 
eight-well chamber slide (Nunc, Inc., Naperville, IL). PBMC 
were cultured in RPMI 1640 supplemented with 10% heat-inac- 
tivated human AB serum. 
Where specified, IL-10 production was stimulated by the addi- 
tion of 1 txg/ml LPS from Escherichia coli (Serotype No. 0127:B8; 
Sigma Immunochemicals, St. Louis, MO) to SFM. For metabolic 
labeling, 10 ~' cytotrophoblasts were cultured for 12 h in 1 ml cys- 
teine- and methionine-deficient DME containing 500 I~Ci 
Tran35S-label TM (ICN Biomedicals Inc., Costa Mesa, CA). 
Quantification of IL-10 in Conditioned Medium (CM) and Cell 
Extracts. CM was collected after 24 h and centrifuged at 300 g 
for 8 rain. CM was then concentrated using Centriprep (5-15 ml 
I Abbreviations u ed in this paper: CM, conditioned medium; HPRT, hy- 
poxanthine-guanine phosphoribosyltransferase; MLIK, nfixed lymphocyte 
reaction. 
medium) or Centricon (up to 3 m.l medium) concentrators with a 
10,000-mol wt cutoff (Amicon, Inc., Beverly, MA). Cell extracts 
were prepared by adding 1 ml lysis buffer (0.5% NP-40, 150 mM 
NaC1, 25 mM Tris-HC1, pH 7.5) containing 1mM PMSF to the 
cultures. The resulting suspensions were passed 10 times through 
a 26-gauge needle. Lysates were then centrifuged at 16,000 g for 
5 rain to remove cellular debris and filtered through a 0.2-1*m fil- 
ter. CM and lysates were stored at -80~ IL-10 levels were de- 
termined by an ELISA developed in this laboratory as previously 
described (30-32). The sensitivity of the assay is 50 pg/nd. 
Immunocytochemistry. Cells cultured overnight in chamber 
slides were fixed for 15 rain in acetone at -20~ then incubated 
in methanol containing 0.3% H202 for 10 nfin to block endoge- 
nous peroxidase activity. After a l-h incubation in antibody dilu- 
ent (PBS containing 0.7% gelatin from cold-water fish skin; 
Sigma), a mixture of 25 I.~g/ml each of two mAbs to human IL-10 
(19Fl [33] and 12G8 [31, 33]) was added for 48 h at 4~ We 
were unable to detect IL-7 in cytotrophoblast conditioned me- 
dium by ELISA (data not shown). Consequently, as a negative 
control, cytotrophoblasts were exposed to 50 txg/ml of a rat mAb 
to human IL-7 (BVD10-11C10; 33) that was of the same IgG 
subclass as both 19F1 and 12G8. As an additional control, cells 
were exposed to antibody diluent alone. Slides were incubated 
with a 1:100 dilution of biotinylated goat anti-rat lgG (Vector 
Laboratories, Inc., Burlingame, CA) for 60 rain at room tempera- 
ture. ABC reagent solution (Vector) was then added for 60 rain, 
and the peroxidase reaction was developed by incubating with 
3,3'-diaminobenzidine (Vector) containing NiC1. Stained cy- 
totrophoblasts were examined by bright-field optics with an Ax- 
iophot microscope (Carl Zeiss, lnc., Thornwood, NY) and pho- 
tographed with Kodachrome 160 ASA tungsten film (Eastman 
Kodak Co., Rochester, NY). 
Immunoprecipitation. 106 metabolically abeled cells were ex- 
tracted in 1 ml 2.5% Triton dilution buffer (TDB; 34) containing 
5 ~g/ml pepstatin, 10 I.~g/ml chymostatin, 5 I.Lg/ml eupeptin, 10 
l~g/ml antipain, 0.5 nM benzamidin, 0.5 U/ml trasylol, and 1 mM 
PMSF. CM (1 ml) was added to 0.5 ml TDB, and both medium 
and labeled cells were frozen at -80~ before use (1-7 d). Lysates 
and conditioned media were precleared twice with CL2-B beads 
(Pharmacia LKB Biotechnology, Piscataway, NJ) as described 
(35). As an additional preclearing step, supernatants were added 
to 50 b~l of a 30% (vol/vol) slurry of protein A-Sepharose (PAS) 
beads in PBS containing 0.03% NaN 3 and incubated with a rat 
IgG2a mAb to ]3-galactosidase (GLl17, I0 ~g/nfl) for 6 h at 4~ 
with continuous agitation. After 30 min, rabbit anti-rat IgG (10 
btg/rnl; Vector) was added to each tube. The precleared samples 
were then incubated with PAS and 3.3 p,g/ml each of three 
n~_bs to human 1L-10 (12G8, 9D7 [3l], and 19F1 [33]) with 
constant agitation for 12 h at 4~ Rabbit anti-rat IgG (10 ~g/ml; 
Vector) was added after 30 min. PAS beads were then pelleted by 
centrifugation and washed five times with mixed micelle buffer 
and three times with final wash buffer (FWB; 35), with a transfer 
of the beads to clean tubes during the second FWB wash. Beads 
were boiled for 3 rain in Laemmli sample buffer containing 2.5% 
]3-mercaptoethanol and subjected to SDS-PAGE on a 15% acry- 
lamide gel. The gel was fixed for 10 min in glacial acetic acid, in- 
cubated for 1 h in EN3HANCE (DuPont Co., Wilmington, DE), 
rinsed twice in tap water, and incubated in HeO containing 3% 
glycerol for 1 h to precipitate the fluor. The gel was then dried 
and exposed to X-OMAT A1K film (Kodak). 
Analysis of Cytotrophoblast IL-10 mRNA. mRNA was extracted 
from 10 ~' cells using RNAzol TM B (Biotecx Laboratories, Inc., 
Houston, TX) according to the manufacturer's recommenda- 
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tions. RNA was reverse transcribed with murine Moloney leuke- 
mia virus reverse transcriptase (GIBCO B1KL, Bethesda, MD) and 
random hexamer primers (Sigma) as previously described (36, 
37). To quantitate l vels of IL-10 mRNA, cDNA was amplified 
in the presence of a multiple human cytokine competitor plasmid 
otherwise identical to a murine construct described in detail else- 
where (36, 37). Briefly, the competitor plasmid, called DC10, 
consists of tandemly arrayed authentic target sequences into 
which DNA spacers of 75-150 bp were introduced. Target se- 
quences in the competitor construct amplify with equivalent effi- 
ciency in the presence of cDNA, and are easily distinguished 
from the smaller wild-type amplimers by 2% agarose gel electro- 
phoresis and ethidium bromide staining. A competitor for the 
constitutively expressed gene, hypoxanthine-guanine phosphori- 
bosyltransferase (HPRT), was included in DC10, allowing input 
cDNA to be standardized to comparable vels of HPRT expres- 
sion in each sample. 
The first step in quantitating IL-10 mtt.NA was to determine 
the amount ofHPP, T cDNA in each sample as a relative measure 
of total cDNA. In these initial PCR. reactions, equal volumes of 
DC10 were added to equal volumes of each of the cDNA sam- 
ples. The reaction products were separated by electrophoresis and 
visualized by ethidium bromide staining. Samples containing 
large amounts of cDNA relative to DC10 resulted in a brighter 
wild-type band. Next, total cDNA levels were equalized among 
samples by adjusting the amounts of input cDNA while maintain- 
ing a constant concentration of DC10. In samples with a rela- 
tively high concentration fcDNA, a smaller volume was used in 
successive reactions until the ratio of band intensities between 
competitor and wild-type HPRT amplimers was identical in each 
sample. To determine the relative levels of IL-10 transcript in 
each sample, equal amounts of total cDNA, whose volumes were 
determined previously, were then used for amplification of IL-10. 
Competition for reagents between the competitor, whose con- 
centration remained constant, and varying amounts of IL-10 
cDNA in each reaction resulted in different ratios of band intensi- 
ties. As cDNA levels decreased, the larger competitor construct 
was preferentially amplified, resulting in a brighter band. These 
relative amounts of wild-type and competitor reaction products 
provide a semiquantitative determination f relative levels of IL-10 
mP, NA in each sample. Primer sequences were as follows: 
HPRT 3': CCTGCTGGATTACATCAAAGCACTG; HPI<T 
5': TCCAACACTTCGTGGGGTCCT; IL-10 3': ATGCCC- 
CAAGCTGAGAACCAAGACCCAGAC; IL-10 5': TCTCAA- 
GGGGCTGGGTCAGCTATCCCA. 
PCR of Placental Biopsies. Total R.NA was isolated from fro- 
zen, pulverized biopsies of term placenta nd placental bed by us- 
ing P, NAzol TM B (Biotecx Laboratories, Inc., Houston, TX) ac- 
cording to the manufacturer's recommendations and reverse 
transcribed as described above. IL-10 cDNA was amplified using 
primers hown above. 
MLR. PBMC were prepared by centrifugation of blood 
from normal donors on a Ficoll-Hypaque 1077 (Sigma) density 
gradient according to the manufacturer's ecommendation. 10s 
PBMC (responders) were mixed with 105 irradiated (3,000 rad) 
allogeneic PBMC (stimulators) and cultured in triplicate in 
round-bottom icrotiter plates (200 I,d/weU). In some wells, 
CM from individual preparations of cytotrophoblast cells was 
added at a final concentration of 50% (vol/vol). Where specified, 
CM was preabsorbed with 20-0.15 Izg/ml of a function-per- 
turbing antibody to IL-10 (anti-lL-10, 19F1; 23, 38) or an anti- 
[3-galactosidase antibody matched for IgG subclass (control IgG, 
GLl17; 31) for 3 h at 37~ before addition. On day 5, the me- 
dium was harvested and centrifuged for 10 rain at 300 g. An 
ELISA specific for IFN-"/, developed in this laboratory (32), was 
performed to determine l vels of this cytokine in the culture me- 
dium. The sensitivity of the assay is 50 pg/ml. Data were analyzed 
using the Mann-Whitney U test for nonparametric distribution. 
Resu l ts  
Human Placental Cytotrophoblasts Secrete IL-IO In Vitro. 
We first examined cytokine synthesis by a variety of  pla- 
cental cells, using ELISA. To test cytotrophoblast produc- 
tion of  cytokines, we used an in vitro system shown by 
stage-specific antigen expression (reviewed in 1 and 2) to 
model the differentiation of  these cells along the invasive 
pathway in vivo. To obtain the required number of  cells, 
first-trimester cytotrophoblasts were isolated from 5-10 
pooled placentas (n = 16), second-trimester cells from 1-4 
pooled placentas (n = 14), and term cells from a single pla- 
centa (n = 8). Cytotrophoblast populations prepared in this 
way are 95% free of  CD-45-posit ive immune cells, them- 
selves potential cytokine-producing contaminants (25). We 
also analyzed CM from organ cultures of  intact chorionic 
villi. Under  these conditions, syncytiotrophoblasts are the 
primary source of  secreted molecules. Cytokine production 
by other placental cell types, including first-trimester pla- 
cental fibroblasts and the BeWo, JAR,  and JEG choriocar- 
cinoma cells lines, was also investigated. 
We recently showed that purified cytotrophoblasts pro- 
duce IL-113, with highest levels secreted uring the first tri- 
mester of  pregnancy (16). In the present experiments, we 
confirmed previous reports that these cells produce IL-6, 
but neither IL-2, -3, -4, -5, -7, nor IFN-'y were detected 
by ELISA in CM (data not shown). In contrast, all cultures 
contained IL-10 in levels that were >50 pg/ml,  the mini-  
mum sensitivity of  the assay (Fig. 1). There were no signif- 
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Figure 1. IL-10 levels ecreted by cultured human cytotrophoblasts. 
Cytotrophoblasts were isolated from pooled first or second trimester (TM) 
or individual term human placentas. 106 cells were cultured in 1 ml se- 
rum-free medium. After 24 h, CM was collected, and levels of secreted 
IL-10 were quantified by ELISA. Each point represents the level of IL-10 
in the CM of one preparation ofcytotrophoblast cells. Diamonds ignify 
means with 95% confidence intervals. 
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icant differences in the mean IL-10 levels produced by cy- 
totrophoblasts from different gestational ages. However,  
there were substantial differences in the absolute amount of  
IL-10 secreted by cells obtained from different pregnancies. 
Human immune cells secrete IL-10 in vitro after activation 
with agents such as endotoxin (30). Although cytotropho- 
blasts ecreted IL-10 without stimulation, addition o f l  p~g/ml 
LPS to first-trimester cells increased IL-10 secretion ap- 
proximately threefold compared to untreated cells from the 
same preparation. With regard to other placental cell types, 
0.1 g of chorionic villi produced ~2 ng IL-6, but less than 
50 pg of  IL-10, suggesting that syncytiotrophoblasts do not 
produce considerable quantities of  the latter cytokine. In 
addition, neither the CM nor lysates of  placental fibroblasts 
or choriocarcinoma cells contained IL-10. These data sug- 
gest that cytotrophoblasts are the major placental source of  
IL-10 in vitro and that the choriocarcinoma cell lines do 
not secrete this cytokine. 
We used a second experimental pproach to verify that 
human cytotrophoblasts synthesize IL-10. Purified cells 
were cultured for 12 h and immunostained with mAbs spe- 
cific for IL-10. An mAb to IL-7 that was matched for IgG 
subtype was used as a control. Purified cytotrophoblasts 
form aggregates during the first 48 h of  culture when plated 
at subconfluent levels (25). A subset of  such cells reacted 
with IL-10 antibodies (Fig. 2 A), but not with IL-7 anti- 
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Figure 2. lmmunodetection f 1L-II) in 
cultured human cytotrophoblasts. 2.5 • 105 
first-trimester cytotrophoblasts were cultured 
in 500 pA serum-free medium. After 12 h, cells 
were fixed and stained with mAbs to IL-10 
(A) or IL-7 (B), as described in Materials and 
Methods. Bar, 100 p~rn; inset bar, 10 ~m. 
bodies (Fig. 2 B). In accordance with the ELISA data, pla- 
cental fibroblasts and the choriocarcinoma cell lines did not 
stain positively for IL-10. 
Temporal Regulation f lL- l O Production. To establish that 
cytotrophoblasts produce, as well as secrete, IL-10 in vitro, 
we imrnunoprecipitated hisprotein from lysates and CM 
prepared from metabolically radiolabeled cells (Fig. 3). Au- 
toradiography of  the electrophoretically separated imrnu- 
noprecipitates showed a single band corresponding to the 
molecular mass of  human IL-10 (18 kD). This band was 
most prominent in CM collected from cells that had been 
cultured for 12 h, and it decreased in intensity over the 60-h 
culture period. Cell lysates contained much lower, but still 
detectable levels of  IL-10, and again the highest amount 
was seen after 12 h in culture. No specific bands were de- 
tected in immunoprecipitates obtained using an antibody to 
IL-7 (25 kD). These results suggest that cytotrophoblast 
synthesis of  IL-10 is highest during the first 12 h, and that 
this cytokine is rapidly secreted into the medium. This was 
verified by ELISA, which showed that the amount of lL -10 
secreted by cytotrophoblasts dropped after 24 h to levels 
that were below the sensitivity of  the assay. During this 
same period, cytotrophoblast cells cultured under identical 
conditions remain viable as indicated by their continued se- 
cretion of  placental hormones (e.g., human chorionic go- 
nadotropin; 24) and by their expression of  newly synthe- 
sized stage-specific antigens (reviewed in 1 and 2). 
Mechanism of Downregulation of lL-lO Synthesis. To elu- 
cidate the mechanism by which protein synthesis is down-  
regulated, we used a competitive PCR-based method with 
primers specific for human IL-10 to measure mR.NA levels 
in cultured cells. We were unable to detect message for this 
cytokine in samples from control cultures of  placental fi- 
broblasts or the BeWo, JAR,  and JEG cell lines. IL-10 
message was, however, readily detected in first-, second-, 
and third-trimester cytotrophoblasts (Fig. 4) both at the 
time of  isolation (time 0) and after as long as 2 d in vitro 
(48 h). In accordance with the imrnunoprecipitation a d 
ELISA data, the amount of lL -10 mRNA (as normalized to 
HPla.T) decreased with time in culture. Together, these 
data suggest that the decline in IL-10 production in vitro is 
transcriptionally regulated. 
The presence of  IL-10 mP, NA in cytotrophoblasts im- 
mediately after purification suggests that these cells either 
synthesize IL-10 in vivo or are induced to do so by the iso- 
lation procedure. To begin to address this question, we 
used RT-PCR.  to analyze various tissues that are compo- 
nents of  the maternal-fetal interface. Both chorionic villi 
and the portion of  the uterus to which anchoring villi at- 
tach expressed IL-10 rnRNA (data not shown). Since these 
specimens contain a variety of  cell types in addition to cy- 
totrophoblasts, it remains to be determined which of  these 
cells produce IL-10 in vivo. 
Cytotrophoblast IL-10 is Immunoinhibitory. Next, we in- 
vestigated whether it was possible to detect one biological 
activity of  IL-10, namely the ability to inhibit an allogeneic 
immune response, within the complex mixture of  growth 
factors and cytokines that cytotrophoblasts secrete. Specifi- 
cally, we measured the ability ofcytotrophoblast CM to in- 
hibit I FN-y  production in an MLR.  In control experi- 
ments, the addition of 1-100 U rlL-10 to an MLP, inhibited 
IFN-~/secretion i a dose-dependent manner. As previously 
shown, as little as 1 U rlL-10 was su~cient to reduce IFN-~/ 
Figure 3. Human cytotrophoblasts synthesize IL-10 in vitro. Term cy- 
totrophoblasts were metabolically labeled for 12 h beginning at 0, 24, and 
48 h in culture. CM was collected, and a cell extract (EX) was prepared. 
Samples were incubated overnight with mAbs to IL-10 or, as a negative 
control, an mAb to IL-7. The resulting immune complexes were sepa- 
rated on a 15% polyacrylamide gel and exposed to film for 3 d. 
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Figure 4. Relative levels oflL-10 mRNA in human placental cytotro- 
phoblasts over time in culture. Placental cytotrophoblasts were isolated as 
described in Materials and Methods from pooled first r second trimester 
(TM) or individual term placentas, and 1LNA was extracted and reverse 
transcribed, cDNA was amplified by PCR. in the presence of the compet- 
itor plasmid, DC10 (see Materials and Methods), allowing the relative 
levels of IL-10 mRNA to be quantified by comparing the relative 
amounts of the larger competitor sequence ( pper band in each lane) and the 
wild-type transcript (lower band in each lane). The equal relative intensities 
of cDNA and competitor HPRT amplimers in each sample (upper panel) 
indicate that nequal amount of input cDNA was added to each reaction. 
IL-10 transcripts were then quantitated by using these equalized amounts 
of input cDNA in PCIL reactions containing a constant amount of DC10 
(lower panel). Over the course of this experiment (48 h), the larger com- 
petitor construct became preferentially amplified, indicating that IL-10 
mfLNA levels decreased in cytotrophoblasts of all gestational ages with 
time in culture. Results are representative of two experiments. 
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Figure 5. IL-10 in cytotrophoblast CM inhibits IFN-y secretion i  a 
primary MLR. Cytotrophoblast CM (CTB CM) was collected after 12 h 
from individual preparations of cells, and absolute amounts of IL-10 in 
each sample were determined by ELISA. AUoreactive lymphocytes were 
cultured in triplicate as described in Materials and Methods in the pres- 
ence of RPM1 alone (white bar) or 50% (vol/vol) CTB CM from individ- 
ual cell preparations either untreated (black bars) or preabsorbed with I0 
Dg/ml of a neutralizing mAb to IL-10 (hatched bars). After 5 d, CM was 
collected and IFN-'y levels in triplicate cultures were determined by 
ELISA. Data of all experiments are presented asmean + SEM. Asterisks 
denote significant increases in IFN-',/ secretion (P <0.05 by the Mann- 
Whitney U test for nonparametric d stribution). 
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Figure 6. Dose-response inhibition of IFN-y secretion by cytotropho- 
blast IL-IO, CM was collected from cytotrophoblast cells after 12 h in cul- 
ture. Alloreactive lymphocytes were cultured in triplicate as described in
Materials and Methods in the presence of 50% (vol/vol) CM or 1,000 
pg/ml rlL-10, each preabsorbed with 20 to 0.15 btg/ml of a neutralizing 
mAb to IL-10 (anti-IL-10; A) or an isotype-matched control antibody 
(control IgG;/3). Results hown are from two individual experiments and 
represent mean -+ SEM. [], 1,000 pg/ml rlL-10; [], CTB CM. 
levels by ~-'25%, and the function-perturbing antibody 
19F1 reversed this suppressive activity (23). In addition, 
19F1 increased basal IFN-~/ levels by neutralizing endoge- 
nous IL-10 when added alone to an MLR.  These effects 
were not observed when a nonspecific antibody of  the 
same IgG subtype was used as a control. Addition of  CM 
from different preparations of  cytotrophoblasts to an MLR 
had variable effects on IFN-y  production (Fig. 5). How-  
ever, neutralizing IL-10 in cytotrophoblast CM resulted in 
a significant increase in IFN-~/ secretion in many samples 
(n = 8, P <0.05). In these experiments, the ability to stim- 
ulate tFN-y  production positively correlated with the 
amount of  IL-10 in the CM (correlation coefficient i 2 = 
0.86). Titrating 19F1 in the CM of  one preparation of  cy- 
totrophoblasts resulted in a dose-response stinmlation of  
I FN-y  production (Fig. 6 A). Again, the isotype-matched 
control antibody had no effect (Fig. 6 B). These observa- 
tions show that IL-10 secreted by cytotrophohlasts acts to 
inhibit allogeneic lymphocyte reactivity in vitro. 
Discuss ion  
We report that IL-10 secreted by highly purified human 
placental cytotrophoblasts can suppress an allogeneic im- 
mune response in vitro. Human IL-10 is a pleiotropic y- 
tokine that is produced by activated immune cells includ- 
ing human CD4 + T cell clones (Th0, Th l ,  and Th2 cells; 
39), B cells (40), and monocytes (30), by UV-irradiated 
murine keratinocytes (41), and by a variety of  human carci- 
noma cell lines (38). Among its activities, IL-10 suppresses 
both T cell proliferative responses and IFN-y  production 
in MLP,.s when allogeneic ells are used as stimulators (23). 
IL-10 suppresses alloresponses by inhibiting the expression 
of  both MHC class II molecules and the costimulatory 
molecule B7 (42, 43). Alloreactive T ceils, such as those 
generated in these reactions, play a key role in allograft re- 
jection (44). These effects of  IL-10 make it an attractive 
candidate for suppressing transplant rejection and prolong- 
ing graft survival (45). 
To investigate the possibility that IL-10 may be involved 
in protecting the allogeneic fetal "transplant" in human 
pregnancy, we determined whether placental cells synthe- 
size this cytokine. Of  the cells we studied, only primary cy- 
totrophoblasts secreted IL-10 in vitro, in levels ranging 
from 67 to 2,190 pg/ml  during the first 24 h of  culture. 
Our  findings correlate with IL-10 production in several 
human diseases, in which systemic cytokine levels are 
equally variable. For example, serum levels of  IL-10 in pa- 
tients with meningococcal septic shock (46) or diffuse large 
cell lymphoma (47) range from 25 to 64,500 pg/ml and ~<5 
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to 27,143 pg/ml, respectively. Even an inbred population 
of mice injected with an antibody to CD3 displays a nine- 
fold variation in serum concentrations of IL-10 (48). The 
intersample variability of IL-10 production by cytotropho- 
blasts is also reflective of the biologic variation in preg- 
nancy-specific hormone production by different placentas. 
For example, the amount of human placental actogen 
(hPL) released by cultured placentas covers a fivefold range 
of values (49). This is also observed in vivo, where circulat- 
ing levels ofhPL in normal pregnancy range from 3.3 to 25 
~g/ml in the third trimester (50). As each placenta is the 
product of a unique immune and hormonal environment, 
it follows that the production of IL-10 will be regulated 
differently in each pregnancy. 
Purified cytotrophoblasts contain IL-10 mRNA imme- 
diately after the isolation procedure, before culture. Both 
IL-10 gene transcription and subsequent protein secretion 
drop within 24 h in vitro. During this time, cytotropho- 
blasts are actively differentiating asthey do during uterine 
invasion in vivo; they modulate the expression of mole- 
cules whose functions mediate ither maternal immune tol- 
erance (e.g., HLA-G; 10) or invasion (e.g., integrin cell- 
ECM receptors [51] and MMP-9 [24]). We have evidence 
that IL-10 can affect both of these important functions. 
With regard to immune aspects of pregnancy, we show 
here that IL-10 in cytotrophoblast CM inhibits alloreactiv- 
ity. In addition, preliminary data suggest hat endogenous 
IL-10 downregnlates the production of MMP-9, which is 
required for invasion in vitro (25). 
It has been suggested that the maternal immune system 
in pregnancy is biased towards antibody production, while 
harmful cell-mediated immunity is weakened (52). The 
generation of a humoral response is associated with the 
production of Th2-type cytokines, including IL-3, IL-4, 
IL-5, IL-10, and IL-13. Of these, IL-10 directly inhibits 
synthesis of proinflammatory Thl-type cytokines (e.g., 
IFN-'y), thus preventing the development of cytotoxic im- 
mune cells (39, 53). Several groups have demonstrated the 
production of Th2 cytokines by tissues at the maternal- 
fetal interface in nmrine gestation (54, 55). However, the 
precise identity of the cell types producing these cytokines 
has not been elucidated. This report shows that in human 
pregnancy, cytotrophoblasts ecrete IL-10. Consistent with 
the ability of IL-10 to inhibit the production of Thl  
cytokines, we did not detect IFN-',/in purified cytotropho- 
blasts by any of several methods used (56). We postulate 
that the localized production of IL-10 by the placenta 
serves to protect he human fetus by driving the maternal 
immune system away from a potentially deleterious cell- 
mediated Thl  response. 
For IL-10 to function as a local immunoinhibitor in
pregnancy, its levels within the uterine wall must be suffi- 
cient to suppress a harmful maternal immune response. 
Since 100 pg/ml rlL-10 is sufficient to inhibit T cell prolif- 
eration in an MLR. (23), the amount of IL-10 secreted by 
these cells in vitro is in a physiologically relevant range. In 
addition, we and others have detected IL-10 mR.NA in bi- 
opsies of both placenta (57) and placental bed, the decidu- 
alized uterine tissue into which cytotrophoblasts invade. 
IL-10 has also been demonstrated to be present in human 
amniotic fluid (58). Together, these observations suggest 
that this cytokine could be produced in sufficient amounts 
to be active in vivo. We have also shown that cytotropho- 
blast-derived IL-10 is immunosuppressive in vitro, as deter- 
mined by its effect on IFN-y secretion in an MLR. The 
fact that we detected this activity in the complex growth 
factor and cytokine mixture in CM suggests that IL-10 
could play an important role in maintaining the fetal al- 
lograft. 
The significance of placental IL-10 production in vivo is 
difficult to assess in animal models because many aspects of 
human pregnancy are unique. For example, human mono- 
nuclear cytotrophoblasts behave like tumor cells in that they 
migrate deep into the uterine wall, mixing extensively with 
maternal decidual cells (2). Mouse placentation is charac- 
terized by shallow invasion by multinucleate giant cells, 
which results in the formation of a distinct fetal-maternal 
boundary (2). Human pregnancy is also immunologically 
unique, as evidenced by the fact that invasive cytotropho- 
blasts express HLA-G (8-10). It is not known whether 
there is a mouse HLA-G homologue. In addition, the sub- 
stantial difference in the length of gestation in the two spe- 
cies (20 d in the mouse vs. 40 wk in the human) suggests 
that different immunomodulatory mechanisms might be 
required for protection of the allogeneic fetus. Therefore, 
the successful birth of IL-10-deficient mice (59) does not 
exclude the possibility that this cytokine is important for 
the maintenance of human pregnancy. In fact, recent evi- 
dence suggests that IL-10 production is disregulated in 
some reproductive pathologies. IL-10 levels are signifi- 
cantly elevated in the amniotic fluid of small-for-gesta- 
tional-age pregnancies, these being the leading cause of 
perinatal morbidity and mortality (58). Additionally, PBMCs 
isolated from women suffering from recurrent spontaneous 
abortions were found to secrete the Thl  cytokines IFN-',/, 
IL-2, TNF-]3, and TNF-e~ when stimulated with tropho- 
blast antigens in vitro (60). In contrast, the supernatant of 
PBMCs from reproductively normal women contained 
IL-10, with undetectable vels of Thl cytokines. These 
observations of human pregnancy suggest hat IL-10 may 
be an important factor for a healthy, term gestation. 
The observed maternal immune tolerance of the geneti- 
cally foreign fetus in mammalian pregnancy is a complex 
phenomenon. Undoubtedly, multiple mechanisms are in- 
volved in preventing immune rejection of the feto-placen- 
tal unit. The expression of HLA-G by invasive cytotropho- 
blasts is one way by which the human placenta can shield 
the conceptus from an immune attack. In addition to this 
evasive mechanism, the localized secretion of immunoreg- 
ulatory cytokines may be very important in dampening an 
inflammatory immune response. In light of this evidence, it
is tempting to speculate that cytotrophoblast-derived IL-10 
plays a key role in protecting the allogeneic human fetus in 
pregnancy. 
545 Roth et al. 
This work was supported by grants from the National Institutes of Health (HD 26732, HD 30367, AI 
26918, and HL 07185). The DNAX Research Institute is entirely supported by the Schering-Plough Cor- 
poration. 
Address correspondence to Susan J. Fisher, HSW 604, University of California t San Francisco, San Fran- 
cisco, CA 94143-0512. 
Received for publication 28 March 1996 and in revised form 3June 1996. 
References 
1. Damsky, C., A. Sutherland, and S. Fisher. 1993. Extracellular 
matrix 5: adhesive interactions in early mammalian embryo- 
genesis, implantation, and placentation. FASEB (Fed. Exp. 
Soc. Exp. Biol.)J. 7:1320-1329. 
2. Cross, J.C., Z. Werb, and S.J. Fisher. 1994. Implantation and 
the placenta: key pieces of the development puzzle. Science 
(Wash. DC). 266:1508-1518. 
3. Starkey, P.M., I.L. Sargent, and C.W. Redman. 1988. Cell 
populations in human early pregnancy decidua: characteriza- 
tion and isolation of large granular lymphocytes by flow cy- 
tometry. Immunology. 65:129-134. 
4. Beer, A.E., andJ.O. Sio. 1982. Placenta s an immunological 
barrier. Biol. Reprod. 26:15-27. 
5. Sionov, R.V., S. Yagel, N.R. Har, and R. Gallily. 1993. 
Trophoblasts protect the inner cell mass from macrophage 
destruction. Biol. Reprocl. 49:588-595. 
6. Faulk, W.P., and A. Temple. 1976. Distribution of beta2 mi- 
croglobulin and HLA in chorionic villi of human placentae. 
Nature (Lond.). 262:799-802. 
7. Faulk, W.P., A.R. Sanderson, and A. Temple. 1977. Distri- 
bution of MHC antigens in human placental chorionic villi. 
Transplant Proc. 9:1379-1384. 
8. Ellis, S.A., I.L. Sargent, C.W. Redman, and A.J. McMichael. 
1986. Evidence for a novel HLA antigen found on human 
extravillous trophoblast and a choriocarcinoma cell line. Im- 
munology. 59:595-601. 
9. Kovats, S., E.K. Main, C. Librach, M. Stubblebine, S.J. 
Fisher, and R. DeMars. 1990. A class I antigen, HLA-G, ex- 
pressed in human trophoblasts. Science (Wash. DC). 248: 
220-223. 
10. McMaster, M.T., C.L. Librach, Y. Zhou, K.H. Lim, M.J, 
Janatpour, R. DeMars, S. Kovats, C. Damsky, and S.J. Fisher. 
1995. Human placental HLA-G expression is restricted to 
differentiated cytotrophoblasts.J. Immunol. 154:3771-3778. 
11. Redman, C.W. 1990. Are there immunologically mediated 
abortions? If so, which mechanisms? Res. Immunol. 141:169-175. 
12. Siiteri, P.K., and D.P. Stites. 1982. Immunologic and endo- 
crine interrelationships n pregnancy. Biol. Reprod. 26:1-14. 
13. Rocklin, R.E.,J.L. Kitzmiller, and M.D. Kaye. 1979. Immu- 
nobiology of the maternal-fetal re ationship. Annu. Rev. Med. 
30:375-404. 
14. Kauma, S.W., S.L. Aukerman, D. Eierman, and T. Turner. 
199l. Colony-stimulating factor-1 and c-fins expression in 
human endometrial tissues and placenta during the menstrual 
cycle and early pregnancy. J. Clin. Endocrinol. Metabol. 73: 
746-751. 
15. Saito, S., K. Motoyoshi, M. Saito, Y. Kato, M. Enomoto, K. 
Nishikawa, T. Morii, and M. Ichijo. 1993. Localization and 
production of human macrophage colony-stinmlating factor 
(hM-CSF) in human placental and decidual tissues. Lympho- 
kine Cytokine Res. 12:101-107. 
16. Librach, C.L., S.L. Feigenbaum, K.E. Bass, T.Y. Cui, N. Ve- 
rastas, Y. Sadovsky, J.P. Quigley, D.L. French, and S.J. 
Fisher. 1994. Interleukin-1 beta regulates human cytotropho- 
blast metalloproteinase ctivity and invasion in vitro. J. Biol. 
Chem. 269:17125-17131. 
17. Kameda, T., N. Matsuzaki, K. Sawai, T. Okada, F. Saji, T. 
Matsuda, T. Hirano, T. Kishimoto, and O. Tanizawa. 1990. 
Production of interleukin-6 by normal human trophoblast. 
Placenta. 11:205-213. 
18. Nishino, E., N. Matsuzaki, K. Masuhiro, T. Kameda, T. 
Taniguchi, T. Takagi, F. Saji, and O. Tanizawa. 1990. Tro- 
phoblast-derived interleukin-6 (IL-6) regulates human chori- 
onic gonadotropin release through IL-6 receptor on human 
trophoblasts.J. Clin. Endocrinol. Metabol. 71:436-441. 
19. Kauma, S., D. Matt, S. Strom, D. Eierman, and T. Turner. 
1990. Interleukin-1 beta, human leukocyte antigen HLA-DR 
alpha, and transforming growth factor-beta expression i en- 
dometrium, placenta, and placental membranes. Am..l. Obstet. 
Gynecol. 163:1430-1437. 
20. Dungy, L.J., T.A. Siddiqi, and S. Khan. 199l. Transfomfing 
growth factor-beta 1 expression during placental develop- 
ment. Am.J. Obstet. Gynecol. 165:1853-1856. 
21. Silver, R.K., J.M. Turbov, J.A. Beaird, and J, Golbus. 199(t. 
Soluble factors produced by isolated first-trimester chorionic 
villi directly inhibit proliferation ofT cells. An1.J. Obstet. Gy- 
necol. 163:1914-1919. 
22. Sanyal, M.K., C.J. Brami, P. Bischof, E. Simmons, E.R. Bar- 
nea, J.M. Dwyer, and F. Naftolin. 1989. Immunoregulatory 
activity in supernatants from cultures of normal human tro- 
phoblast cells of the first trimester. Am. J. Obstet. Gynecol. 
161:446-453. 
23. Bejarano, M.T., R. de Waal Malefyt, J.S. Abrams, M. Bigler, 
R. Bacchetta, J. de Vries, and M.G. Roncarolo. 1992. Inter- 
leukin 10 inhibits allogeneic proliferative and cytotoxic T cell 
responses generated in primary mixed lymphocyte cultures. 
hit. Immunol. 4:1389-1397. 
24. Fisher, S.J., T.Y. Cui, L. Zhang, L. Hamnan, K. Grahl, G.Y. 
Zhang, J. Tarpey, and C.H. l)amsky. 1989. Adhesive and 
degradative properties of human placental cytotrophoblast 
cells in vitro._/. Cell Biol. 109:891-902. 
25. Librach, C.L., Z. Werb, M.L. Fitzgerald, K. Chiu, N.M. 
Corwin, R.A. Esteves, D. Grobelny, R. Galardy, C.H. l)am- 
sky, and S.J. Fisher. 1991. 92-kD type IV collagenase inedi- 
546 Placental Interleukin 10 Is lmmunosuppressive 
ates invasion of human cytotrophoblasts. J. Cell Biol. 113: 
437-449. 
26. Kliman, H.J., J.E. Nestler, E. Sermasi, J.M. Sanger, and J.F. 
Strauss III. 1986. Purification, characterization, and in vitro 
differentiation of cytotrophoblasts from human term placen- 
tae. Endocrinology. 118:1567-1582. 
27. Pattillo, R.A., A.C. Ruckert, R.O. Hussa, R. Bernstein, and 
E. Delfs. 1971. The JAR cell line: continuous human multi- 
hormone production and controls. In Vitro. 6:398-405. 
28. Pattillo, R.A., and G.O. Gey. 1968. The establishment of a 
cell line of human hormone-synthesizing trophoblastic cells 
in vitro. Cancer Res. 28:1231-1236. 
29. Kohler, P.O., and W.E. Bridson. 1971. Isolation of hor- 
mone-producing clonal lines of human choriocarcinoma. J. 
Clin. Endocrinol. Metabol. 32:683-687. 
30. de Waal Male@t, R., J. Abrams, B. Bennett, C.G. Figdor, 
andJ. de Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine 
synthesis by human monocytes: an autoregulatory role of IL-10 
produced by monocytes.J. Exp. Med. 174:1209-1220. 
31. Abrams, J.S., M.G. Roncarolo, H. Yssel, U. Andersson, GJ. 
Gleich, and J.E. Silver. 1992. Strategies of anti-cytokine 
monoclonal antibody development: immunoassay of IL-10 
and IL-5 in clinical samples. Immunol. Rev. 127:5-24. 
32. Abrams, J.S. 1995. Immunoenzymetric assay of mouse and 
human cytokines using NIP-labeled anti-cytokine antibodies. 
/n Current Protocols in Immunology. J E. Coligan, A.M. 
Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, 
editors. John Wiley & Sons, New York. Unit 6.20. 
33. Andersson, J., S. Nagy, L. Bjork, J. Abrams, S. Holm, and U. 
Andersson. 1992. Bacterial toxin-induced cytokine produc- 
tion studied at the single-cell evel. Immunol. Rev. 127:69-96. 
34. Casanova, J.E., G. Apodaca, and K.E. Mostov. 1991. An au- 
tonomous ignal for basolateral sorting in the cytoplasmic do- 
main of the polymeric immunogtobutin receptor. Celt. 66: 
65-75. 
35. Breitfeld, P.P., J.E. Casanova, J.M. Hams, N.E. Simister, and 
K.E. Mostov. 1989. Expression and analysis of the polymeric 
immunoglobulin receptor in Madin-Darby canine kidney 
cells using retroviral vectors. Methods Cell Biol. 32:329-337. 
36. Reiner, S.L., S. Zheng, D.B. Corry, and R.M. Locksley. 
1993. Constructing polycompetitor cDNAs for quantitative 
PCR. J. Immunol. Methods. 165:37-46. 
37. Corry, D.B., H.G. Folkesson, M.L. Warnock, DJ. Erle, 
M.A. Matthay, KJ. Wiener, and R.M. Locksley. 1996. In- 
terleukin 4, but not interleukin 5 or eosinophils, is required 
in a murine model of acute airway hyperreactivity [see com- 
ments].J. Exp. Med. 183:109-117. 
38. Gastl, G.A., J.S. Abrams, D.M. Nanus, R. Oosterkamp, J. 
Silver, F. Liu, M. Chen, A.P. Albino, and N.H. Bander. 
1993. Interleukin-10 production by human carcinoma cell 
lines and its relationship to interleukin-6 expression. Int. J. 
Cancer. 55:96-101. 
39. Moore, K.W., A. O'Garra, R. de Waal Male@t, P. Vieira, 
and T.R. Mosmann. 1993. lnterleukin-10. Annu. Rev. Immu- 
noI. 11:165-190. 
40. Matthes, T., F.C. Werner, H. Tang, X. Zhang, V. Kindler, 
and R.H. Zubler. 1993. Cytokine mRNA expression during 
an in vitro response of human B lymphocytes: kinetics of B 
cell tumor necrosis factor alpha, interleukin (IL)6, IL-10, and 
transforming growth factor beta 1 mlKNAs.J. Exp. Med. 178: 
521-528. 
41. Rivas, J.M., and S.E. Ullrich. 1992. Systemic suppression of 
delayed-type hypersensitivity b supematants from UV-irra- 
diated keratinocytes. An essential role for keratinocyte- 
derived IL-10.J. Immunol. 149:3865-3871. 
42. de Waal Male@t, R., J. Haanen, H. Spits, M.G. Roncarolo, 
A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, 
and J. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 
strongly reduce antigen-specific human T cell proliferation 
by diminishing the antigen-presenting capacity of monocytes 
via downregulation f class II major histocompatibility com- 
plex expression.J. Exp. Med. 174:915-924. 
43. Ding, L., P.S. Linsley, L.Y. Huang, IK.N. Germain, and E.M. 
Shevach. 1993. IL-10 inhibits macrophage costimulatory ac- 
tivity by selectively inhibiting the up-regulation of B7 ex- 
pression. J. Immunol. 151 : 1224-1234. 
44. Ferrara, J.L., and HJ. Deeg. 1991. Graft-versus-host disease 
[see comments]. N. Engl.J. Med. 324:667-674. 
45. Howard, M., and A.O'Garra. 1992. Biological properties of 
interleukin 10. Immunol. Today. 13:198-200. 
46. Lehmann, A.K., A. Halstensen, S. Somes, O. Rokke, and A. 
Waage. 1995. High levels ofinterleukin 10 in serum are asso- 
ciated with fatality in meningococcal disease. Infect. Immun. 
63:2109-2112. 
47. Cortes, J.E., M. Talpaz, F. Cabanillas, J.F. Seymour, and R. 
Kurzrock. 1995. Serum levels of interleukin-10 in patients 
with diffuse large cell lymphoma: lack of correlation with 
prognosis. Blood. 85:2516-2520. 
48. Durez, P., D. Abramowicz, C. Gerard, M.M. Van, Z. Am- 
raoui, C. Dubois, O. Leo, T. Velu, and M. Goldman. 1993. 
In vivo induction ofinterleukin 10 by anti-CD3 monoclonal 
antibody or bacterial lipopolysaccharide: ifferential modula- 
tion by cyclosporin A.J. Exp. Med. 177:551-555. 
49. Suwa, S., and H. Friesen. 1969. Biosynthesis of human pla- 
cental proteins and human placental lactogen (HPL) in vitro. 
II. Dynamic studies of normal term placentas. Endocrinology. 
85:1037-1045. 
50. Buster, J.E., and J.A. Simrn. 1989. Placental hormones, hor- 
monal preparation for and control of parturition, and hor- 
monal diagnosis of pregnancy. In Endocrinology. LJ. DeGroot, 
editor. W.B. Saunders Company, Philadelphia. 3:2043-2073. 
51. Damsky, C.H., C. Librach, K.H. Lim, M.L. Fitzgerald, M.T. 
McMaster, M. Janatpour, Y. Zhou, S.K. Logan, and SJ. 
Fisher. 1994. Integrin switching regulates normal trophoblast 
invasion. Development (Camb.). 120:3657-3666. 
52. Wegmann, T.G., H. Lin, L. Guilbert, and T.R. Mosmann. 
1993. Bidirectional cytokine interactions in the maternal-fetal 
relationship: is successful pregnancy a TH2 phenomenon? 
Immunol. Today. 14:353-356. 
53. Fiorentino, D.F., M.W. Bond, and T.R. Mosmann. 1989. 
Two types of mouse T helper cell. IV. Th2 clones secrete a
factor that inhibits cytokine production by Thl clones. J. 
Exp. Med. 170:2081-2095. 
54. Lin, H., T.R. Mosmann, L. Guilbert, S. Tuntipopipat, and 
T.G. Wegmann. 1993. Synthesis of T helper 2-type cyto- 
kines at the maternal-fetal interface. J. Immunol. 151:4562- 
4573. 
55. Delassus, S., G.C. Coutinho, C. Saucier, S. Darche, and P. 
Kourilsky. 1994. Differential cytokine xpression i maternal 
blood and placenta during murine gestation.J. Immunol. 152: 
2411-2420. 
56. Roberts, R.M., J.C. Cross, C.E. Farin, P.W. Farin, K.K. 
Kramer, H. Francis, C. Librach, and S.J. Fisher. 1991. Tro- 
phoblast interferons. In Growth Factors in Reproduction. 
547 Roth et al. 
D.W. Schombergs. Springer-Verlag, New York. 235-245. 
57. Cadet, P., P.L. Rady, S.K. Tyring, R.B. Yandell, and T.K. 
Hughes. 1995. Interleukin-10 messenger ribonucleic acid in 
human placenta: implications of a role for interleukin-10 in
fetal allograft protection. Am.J. Obstet. Gynecol. 173:25-29. 
58. Heyborne, K.D., J.A. McGregor, G. Henry, S.S. Witkin, and 
J.S. Abrams. 1994. Interleukin-10 in amniotic fluid at midtri- 
mester: immune activation and suppression i relation to fetal 
growth. Am. J. Obstet. Gynecol. 171:55-59. 
59. Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, and W. 
Muller. 1993. Interleukin-10-deficient mice develop chronic 
enterocolitis [ ee comments]. Cell. 75:263-274. 
60. HiI1,J.A., K. Polgar, and D.J. Anderson. 1995. T-helper 1-type 
immunity to trophoblast in women with recurrent spontane- 
ous abortion [see comments].J. Am. Med. Assoc. 273:1933- 
1936. 
548 Placental Interleukin 10 Is Immunosuppressive 
